What is CBC (cannabichromene)?

Cannabichromene (CBC) is a non-intoxicating cannabinoid first isolated from hashish in 1966. The plant makes it from CBGA through the enzyme CBCA synthase. CBC binds only weakly to CB1, the receptor behind THC's high. Laboratory studies show activity at TRP channels, and in human sebocytes it reduced sebum-lipid production.

Among the many compounds in Cannabis sativa L., one that has been drawing more attention in recent years is cannabichromene, or CBC. First discovered in 1966, it has gradually gained recognition as both researchers and industry professionals take a closer look.

Unlike THC, CBC is not associated with psychoactive effects, which makes it especially interesting in scientific studies.

Exploring CBC involves examining how it interacts with specific receptors in the body. This helps place it within the larger cannabinoid framework, offering deeper insight into the natural complexity of the plant.

Prefer watching over reading? This video covers the key points from the article:

Key takeaways

• Cannabichromene (CBC) is a non-psychoactive cannabinoid identified in 1966.
• CBC forms through the enzymatic conversion of cannabigerolic acid (CBGA) into cannabichromenic acid (CBCA), which later decarboxylates into CBC.
• Unlike THC, CBC does not strongly bind to CB1 receptors in the brain.
• CBC interacts with other receptors in the body, contributing to its distinct biochemical profile.
• CBC is typically present in lower concentrations in hemp and cannabis plants compared to CBD and THC.

Introduction to CBC (cannabichromene)

Cannabichromene (CBC) is a non-psychoactive cannabinoid found in Cannabis sativa. Unlike THC and CBD, it interacts with the body’s receptor systems in distinct ways, which has drawn scientific interest for further study.

To understand CBC, researchers focus on its chemical structure, how it develops in the plant and how it connects with receptors such as TRP and CB2. These receptors are involved in various natural processes, offering a foundation for understanding CBC’s unique role in cannabinoid science.

CBC originates from CBGA, the precursor molecule that also gives rise to several other cannabinoids. This early role in synthesis highlights its relevance when studying plant-based compounds.

It was first isolated in 1966, independently by Yehiel Gaoni and Raphael Mechoulam in Israel and by a German group led by Claussen. Their findings marked the discovery of CBC as a natural cannabinoid in Cannabis sativa.

Although CBC is less abundant than THC or CBD, its distinct behaviour at the molecular level continues to make it a subject of growing interest. Ongoing studies aim to clarify its role and characteristics.

What is Cannabis sativa?

CBC is usually a minor cannabinoid, but it is measurable in full-spectrum hemp extracts. In our own lab, CBC measured 0.82% by weight in our Zermatt Balance oil and 1.51% in St. Moritz Restore (report 260410_A01, samples 260408.03 and 260408.04). See our lab reports.

Chemical structure of CBC

CBC shares a biosynthetic pathway with other cannabinoids through CBGA. When CBGA is converted into CBCA via enzymatic processes, and CBCA is later exposed to heat, for example during drying, it undergoes decarboxylation to form CBC. Its chemical formula is C₂₁H₃₀O₂, and while its structure resembles that of THC and CBD, small differences influence its receptor activity.

CBC’s structure includes a two-ring chromene (benzopyran) core with a pentyl side chain and a methylpentenyl side chain, features that support its solubility in lipids and its function in formulations studied alongside other cannabinoids and terpenes.

Unlike THC, CBC does not bind strongly with CB1 receptors, which is consistent with its lack of intoxicating effects. Scientists are continuing to investigate how its molecular shape contributes to its activity in cannabinoid-focused studies.

The complex biochemistry behind CBC

The journey of cannabichromene (CBC) from biosynthesis to receptor interaction reveals a detailed biochemical pathway. This provides insight into its characteristics both in plant biology and in laboratory research.

As noted in a review of cannabigerol (CBG) published in the journal Molecules, CBC originates from cannabigerolic acid (CBGA). Through the enzyme CBCA synthase, CBGA is converted into cannabichromenic acid (CBCA).

CBCA then undergoes decarboxylation, usually triggered by heat and drying, to form CBC in its neutral form.

A review published in the Journal of Pharmacology and Experimental Therapeutics highlights that CBC shows little activity at CB1 receptors, acts as an agonist at CB2 receptors in cell-based studies and is considered non-intoxicating.

Alongside this CB2 activity, CBC may influence the endocannabinoid system indirectly. In laboratory studies it inhibited the cellular uptake of anandamide (AEA) but not the AEA-degrading enzyme FAAH, while reports on its effect on the 2-AG-degrading enzyme MAGL are mixed.

The endocannabinoid system (ECS)

CBC also interacts with transient receptor potential (TRP) channels, which help detect physical and chemical stimuli. These receptor interactions contribute to CBC’s broader scientific profile.

By mapping out CBC’s effects across receptor systems, researchers aim to build a clearer picture of its role within cannabinoid science.

The interest in cannabichromene (CBC)

CBC continues to attract attention, especially in the study of non-psychoactive cannabinoids. Its unique receptor interactions make it an important area of ongoing research.

Current work includes examining its effects in sensory-related systems under controlled laboratory settings, helping generate reference points for further studies.

Research is also exploring how CBC relates to behavioural models, although this is still at an early stage and requires careful review. Laboratory studies on specific cell lines are helping expand understanding of how cannabinoids work in biological systems.

As knowledge grows, CBC is becoming an increasingly relevant subject in cannabinoid research, particularly within the category of non-psychoactive compounds.

A closer look at CBC research and studies

Recent investigations have compared CBC to other cannabinoids such as CBD, highlighting differences in how they interact with receptor systems beyond CB1 and CB2.

In mice, CBC produced some cannabinoid-like effects and reduced inflammatory paw swelling, through a mechanism that did not involve CB1 or CB2 receptors (DeLong et al., 2010). In the same study, a small dose of THC increased CBC's effects.

CBC and skin cells

In cultured human sebocytes, the cells that make skin oil, CBC suppressed basal lipid production and reduced "acne-like" lipid production triggered by arachidonic acid. It also had anti-inflammatory effects, and at concentrations up to 10 µM it barely affected cell viability (Oláh et al., 2016). This is a cell study, not a clinical trial.

Research in the Journal of Pharmacology and Experimental Therapeutics supports CBC’s limited CB1 affinity, CB2 agonist activity in cell studies and its distinct non-psychoactive profile.

In addition to its activity at CB2 receptors and TRP channels, CBC may influence the endocannabinoid system indirectly and shape the activity of other cannabinoids. Ongoing work is needed to map its full profile.

What are cannabinoids?

Exploring the future of CBC

CBC is steadily gaining attention in cannabinoid research. Unlike THC, it does not produce intoxicating effects, which makes it a useful subject for studying non-psychoactive cannabinoid activity.

Research published in Comparative Clinical Pathology has investigated, in an animal study, CBC’s possible neuromodulatory effects involving the TrkB/BDNF signalling pathway. Studies like this underline the importance of continued exploration.

Ongoing research is focusing on CBC’s potential involvement in neurological and sensory-related pathways, as well as its place within the broader entourage effect, where cannabinoids and terpenes may influence each other’s activity.

CBC is currently being studied in laboratory and preclinical environments. Larger, structured human studies will be necessary to draw more complete conclusions about its role.

For now, CBC remains a subject of active investigation, followed closely by researchers and industry professionals. Its growing profile reflects the expanding scope of cannabinoid science and the effort to understand the complexity of Cannabis sativa.

The complete list of cannabinoids